8-K: PacBio Announces Preliminary Q1 2024 Results, Reduces 2024 Revenue Guidance and Plans Cost Cuts

PacBio reported preliminary Q1 2024 revenue that was below expectations, leading to a reduced 2024 revenue guidance and a plan to cut operating expenses by $50-$75 million.

Summary

• PacBio's preliminary revenue for Q1 2024 was $38.8 million, which is roughly flat compared to the $38.9 million in the same period last year.
• Instrument revenue was $19.0 million, down from $20.7 million year-over-year, while consumables revenue increased to $16.0 million from $14.0 million.
• The company shipped 28 Revio sequencing systems in Q1, bringing the total installed base to 201 systems.
• PacBio's preliminary cash, cash equivalents, and investments balance was approximately $562 million as of March 31, 2024.
• The company is reducing its 2024 revenue guidance to a range of $170 million to $200 million, down from previous expectations.
• PacBio plans to reduce its annualized run-rate operating expenses by $50 million to $75 million by the end of 2024.
• The company now expects to end 2024 with a cash balance between $435 million and $450 million.
• PacBio believes it is unlikely to achieve its long-term revenue guidance of at least $500 million in 2026 and is reevaluating the timing of achieving it.

Sentiment

Score: 3

Explanation: The document conveys a negative sentiment due to the revenue miss, reduced guidance, and planned cost cuts. While there are some positive points, the overall tone is cautious and indicates significant challenges.

Positives

• Consumables revenue increased year-over-year to $16.0 million.
• The installed base of Revio systems reached 201, with 16 of the 28 shipped in Q1 going to new customers.
• Onso shipments increased sequentially, reaching steady-state production levels by the end of the quarter.
• March Revio utilization was at an all-time high, with some top customers exceeding expectations.
• The company has launched a v13 software upgrade and new reagent kits to improve customer workflows.
• PacBio is seeing traction with large-scale projects, such as the Estonia National Biobank project.

Negatives

• Preliminary Q1 revenue was below expectations due to delayed instrument purchases and softness in consumable shipments.
• Instrument revenue decreased year-over-year to $19.0 million.
• All regions underperformed, with 13 Revio systems falling out of the forecast in the last couple of weeks of Q1.
• The median sales cycle for Revio instrument purchases increased more than expected.
• Consumable revenue was also below expectations due to slower ramp-up in sequencing by smallto mid-sized customers and sample delays.
• The company has reduced its 2024 revenue guidance to $170 million to $200 million.
• PacBio believes it is unlikely to achieve its long-term revenue guidance of at least $500 million in 2026.

Risks

• The company faces risks related to delayed instrument purchases and slower-than-expected consumable growth.
• Uncertainty surrounding funding for new capital equipment, particularly in the U.S. and China, is impacting sales.
• Procurement delays and longer sales cycles for new customers are contributing to the revenue shortfall.
• The company's cost reduction initiatives may have an adverse impact on the business and results of operations.
• The charges associated with the operating expense reductions may be greater than anticipated.
• The company's financial results could differ materially from the preliminary estimates.

Future Outlook

PacBio expects second quarter revenue to improve over the first quarter and that the second half of the year will improve sequentially as consumables return to sequential growth and the company closes some of the deals that were delayed in the first quarter. The company is reevaluating the timing of achieving its long-term revenue guidance of at least $500 million in 2026.

Management Comments

• Christian Henry, President and CEO of PacBio, stated that the first quarter came in below expectations due to delayed instrument purchases and softness in consumable shipments.
• He also mentioned that the company is focused on improving commercial execution, continuing the development of new platforms, improving gross margin, and reducing operating expenses.
• He expressed confidence in the company's ability to create value for stockholders and stakeholders.

Industry Context

The announcement reflects challenges in the genomics sequencing industry, where capital equipment purchases can be sensitive to funding environments and customer adoption rates can vary. The company's focus on cost reduction and improving commercial execution is a common response to such challenges.

Comparison to Industry Standards

• PacBio's revenue miss and revised guidance are concerning when compared to other life science companies that have shown more stable growth.
• Companies like Illumina, while facing their own challenges, have generally maintained more consistent revenue streams.
• The increased sales cycle for PacBio's Revio system is a negative signal compared to the more rapid adoption seen with some competing technologies.
• The planned cost reductions are similar to actions taken by other companies in the sector facing headwinds, but the magnitude of the reduction suggests a significant impact on operations.

Stakeholder Impact

• Shareholders will likely react negatively to the reduced revenue guidance and cost-cutting measures.
• Employees may be impacted by the planned operating expense reductions.
• Customers may experience delays or changes in service due to the company's restructuring.
• Suppliers may see changes in order volumes due to the company's revised outlook.

Next Steps

• PacBio will hold its Q1 2024 earnings conference call on May 9, 2024, to discuss its financial results and outlook.
• The company will provide further details on its full-year outlook on the earnings call.
• PacBio will provide further details on the estimated costs for the planned operating expense reductions by amendment to this Current Report on Form 8-K.

Key Dates

Keywords

PacBio, Genomics, Sequencing, Revio, Onso, Revenue, Consumables, Operating Expenses, Financial Guidance, Cost Reduction